-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Houston - The second phase of the study by researchers at the University of Texas MD Anderson Cancer Center found that atezolizumab and bevacizumab treatments were well tolerated and resulted in an objective response rate of 40% in the abdomen of patients with advanced malignant peritoneal mesothelioma Rare cancer of the inner layer
The test results show that the combination therapy is safe and effective for patients with disease progression or intolerance to previous chemotherapy
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive disease with historically poor survival and limited treatment options
"The needs of patients with peritoneal mesothelioma are seriously unmet," Raghav said
One of the first trials for mpm patients
Researchers estimate that 300-500 Americans are diagnosed with multiple polio every year
There are many treatment strategies, but they usually include the best cytoreduction surgery, intraoperative hypothermic intraperitoneal infusion chemotherapy (HIPEC), or early postoperative intraperitoneal chemotherapy (EPIC)
The National Comprehensive Cancer Network (NCCN) recommends two first-line platinum chemotherapy for mesothelioma, but after the disease progresses, there is no definite treatment strategy or any FDA-approved treatment for advanced MPeM
This single-center study is a multi-cohort basket trial to evaluate the efficacy of atezolizumab and bevacizumab in various advanced cancers
Before participating in this clinical trial, patients who received standard-of-care chemotherapy progressed to the next treatment after 8.
The 1-year progression-free survival rate and overall survival rate were 61% and 85%, respectively
Raghav said: "The efficacy of this therapy has exceeded the expectations of traditional therapies
Biomarker analysis
The integration of biopsy before and during treatment establishes the practicality and value of rare cancer transformation motivation methods
Biomarker analysis identified epithelial-mesenchymal transition (EMT) gene expression, a cancer state associated with more aggressive biology, associated with aggressive disease, treatment resistance, and poor response rates
To determine the predictive response of the tumor environment to this drug treatment, the researchers used 15 patient samples to examine the subset of immune cells before treatment
"I am very encouraged by the response to this treatment, and I hope that with more research, this will provide these patients with better treatment options," Raghav said
More patients are needed to participate in trials to validate these findings and determine whether this drug combination can be used as a first-line treatment or to improve the surgical outcome of these patients
# # #